Prothena Corporation plc is a late-stage clinical
         biotechnology company focused on the discovery,
      development and commercialization of novel
   protein immunotherapy programs for the
  potential treatment of diseases that
involve amyloid or cell adhesion.

LATEST NEWS

SPOTLIGHT

Potential Mechanism of Action (MOA) Videos:

vid_neod001
for AL Amyloidosis
vid_prx002
for Parkinson’s Disease and
Other Related Synucleinopathies
vid_prx003
for Psoriasis and Other
Inflammatory Diseases